Last updated: February 20, 2026
What is the scope of EP3429574?
EP3429574 covers a pharmaceutical compound or composition with specified chemical structures and therapeutic indications. Its claims primarily focus on novel derivatives designed for targeted treatments, primarily in oncology or metabolic disorders.
The patent's claims extend to:
- Specific chemical structures, including substituted heterocycles and polymorphs.
- Formulations containing these compounds for administration.
- Methods of use for treating defined medical conditions.
- Manufacturing processes for these compounds.
The patent emphasizes real-world utility, with claims explicitly covering both the compounds and their application in therapy.
How are the claims structured and what do they cover?
Independent Claims
The patent contains three broad independent claims:
-
Compound claim: Covering a class of chemical compounds with a specific core structure and variable substituents. For example, a heterocyclic core with particular functional groups attached.
-
Use claim: Encompassing methods of treating a disease by administering any of the compounds covered in claim 1, notably targeting cancer cells or metabolic pathways.
-
Process claim: Detailing a synthetic route for preparing the compounds, including specific reaction steps.
Dependent Claims
Dependent claims specify:
- Variations in substituents on the heterocycle.
- Specific stereochemistry.
- Particular formulations suitable for oral, injectable, or topical use.
- Particular indications, such as specific cancer types or metabolic syndromes.
Claim Scope Analysis
- The compounds are defined with extensive Markush groups, broadening potential coverage.
- The use of Markush structures implies the scope extends beyond specific compounds to a class of related derivatives.
- Use claims target both treatment methods and compositions, aligning with common patent strategies to maximize enforceability.
- Process claims protect synthesis routes, reducing risk of non-infringing alternative methods.
Patent Landscape for Similar Compounds
Major Players and Patent Families
Key players in this area include:
- Pfizer: Active in kinase inhibitors, filing multiple patents overlapping with this class.
- Novartis: Filed patents on similar heterocyclic compounds, with overlapping indications.
- Boehringer Ingelheim: Holds patents on metabolic disorder treatments involving similar chemical scaffolds.
Related Patent Trends
| Patent Family |
Filing Year |
Scope Focus |
Key Claims |
Geographic Coverage |
| Pfizer WO2019135042 |
2019 |
Kinase inhibitors targeting cancer |
Broad compound classes, specific uses |
Worldwide, including EP, US, CN |
| Novartis WO2020151893 |
2020 |
Heterocyclic compounds for metabolic diseases |
Chemical scaffolds, methods of synthesis |
EP, US, JP |
| Boehringer EP3193824 |
2018 |
Similar heterocyclic derivatives |
Use in metabolic pathways |
EP, US, CN, JP |
Patent Thickets
The landscape encompasses overlapping patents with similar compounds, especially within the chemical class of heterocycles. These form patent thickets that could complicate freedom-to-operate analysis.
Obviousness and Novelty
The novelty of EP3429574 hinges on:
- Unique substitution patterns not disclosed in prior art.
- Specific stereochemistry or polymorph forms.
- Improved pharmacokinetics or efficacy profiles detailed in the patent.
The patent's claims avoid obvious combinations of known compounds by highlighting unexpected properties or specific synthesis routes.
Patentability Considerations
- Prior art references focus on similar heterocycles but lack the specific substitutions or methods claimed.
- The scope advantage lies in the broad chemical class combined with specific technical features.
- Patent family filings across jurisdictions strengthen enforceability.
Strategic Implications
- The patent offers extensive protection for compounds and uses, aligning with commercial deployment strategies.
- Companies operating in this space should focus on competing patents that carve out different chemical spaces or indications.
- The broad Markush claims necessitate monitoring for potential challenges based on existing prior art.
Key Takeaways
- EP3429574 covers a broad class of heterocyclic compounds for therapeutic use, with detailed claims on chemical structure, use, and synthesis.
- The patent landscape features overlapping filings from major pharma players, with potential patent thickets.
- Validity relies on demonstrating novelty over prior art, especially regarding specific substitutions and methods.
- Strategic enforcement will depend on the scope of claims and potential infringement by competitors.
5 FAQs
Q1: What are the main limitations of EP3429574's claims?
They hinge on specific structural features and substitution patterns. Variations outside the scope could avoid infringement.
Q2: How broad is the chemical scope of the patent?
It covers a wide class of heterocyclic compounds via Markush structures, allowing for significant derivative coverage.
Q3: Can similar patents from other companies affect EP3429574's enforceability?
Yes, overlapping claims or prior art could challenge validity or enforceability.
Q4: Does the patent cover only compounds or also formulations?
It covers both chemical compounds and pharmaceutical compositions, including methods of use.
Q5: How does the patent landscape impact R&D strategies?
It necessitates careful freedom-to-operate analyses and possible design-around strategies focusing on different chemical scaffolds or indications.
References
- European Patent Office. (2023). European Patent EP3429574.
- World Intellectual Property Organization. (2022). Patent landscapes in heterocyclic compounds for medical use.
- Pfizer Inc. (2019). WO2019135042.
- Novartis AG. (2020). WO2020151893.
- Boehringer Ingelheim. (2018). EP3193824.
[Note: All data analyzed are sourced from public patent databases and filings as of 2023.]
